A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy

Status: Recruiting

Eligibility Criteria

Sex: Male
Age Group: 18 years and over
This study is NOT accepting healthy volunteers

Inclusion Criteria:

- diagnosis of adenocarcinoma of the prostate - cancer progression while on androgen deprivation therapy with metastasis to bone or other areas of the body - received 1 but no more than 2 taxane-based chemotherapy regimens - unable to do strenuous activity but walking and able to carry out work of a light or sedentary nature, e.g., light house work, office work - see link to clinicaltrials.gov for complete inclusion and exclusion criteria

Exclusion Criteria:

- unable to swallow capsules/tablets - gastrointestinal disorder that might affect absorption - poorly controlled diabetes mellitus - history of clinically significant ventricular arrhythmias - known additional cancer that is progressing or has required active treatment within the past 3 years

Conditions & Interventions

Conditions:
Cancer
Keywords:
Clinics and Surgery Center (CSC), mCRPC, metastatic castration-resistant prostate cancer, Prostate Cancer Metastatic

More Information

Description: This trial is testing MK-5684 in men with metastatic castration-resistant prostate cancer (mCRPC) previously treated with next-generation Hormonal Agent (NHA) and Taxane-based chemotherapy. This trial will compare MK-5684 to abiraterone acetate and enzalutamide. Abiraterone acetate and enzalutamide are standard treatments for mCRPC. The purpose of this trial is to test the safety of the trial drug, MK-5684, see how well the drug works, and see how the body handles the drug. We also want to see if participants who get MK-5684 live longer compared to those who get abiraterone acetate or enzalutamide.
Study Contact: Emmanuel Antonarakis - anton401@umn.edu
Principal Investigator: Emmanuel Antonarakis
Phase: PHASE3
IRB Number: STUDY00021305